Epithalon vs NAD+: Two Anti-Aging Compounds from Different Scientific Traditions

Epithalon (AEDG, Ala-Glu-Asp-Gly) is a synthetic tetrapeptide corresponding to a fragment of Epithalamin — a polypeptide isolated from bovine pineal gland extract. Characterized extensively by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1980s.

Epithalon's primary proposed mechanism is telomerase activation. Telomerase is the enzyme that adds TTAGGG telomere repeat sequences to the ends of chromosomes, maintaining telomere length. In most somatic cells, telomerase expression is suppressed — cells undergo a finite number of divisions before telomeres reach critical shortness, triggering senescence or apoptosis (the Hayflick limit).

Khavinson's research showed that Epithalon induced telomerase expression in human fetal somatic cells and lengthened telomeres in cells that would otherwise become senescent. This is one of the few documented cases of pharmacological telomerase activation in normal somatic cells — a mechanism that, if validated broadly, would have significant implications for tissue aging and cellular longevity.

NAD+ (nicotinamide adenine dinucleotide) is not a peptide but a coenzyme present in every cell, central to two validated longevity pathways:

Sirtuin activation: Sirtuins (SIRT1-7) are NAD+-dependent deacylase enzymes regulating DNA repair, inflammation, mitochondrial biogenesis, and metabolic gene expression. NAD+ levels decline approximately 50% between age 40 and 70, directly limiting sirtuin activity. Restoring NAD+ restores the substrate availability for all seven sirtuin family members.

PARP-mediated DNA repair: PARP1 and related enzymes use NAD+ to repair DNA strand breaks. As age-related DNA damage accumulates, PARP activity increases, consuming NAD+ and accelerating the age-related NAD+ decline — a degenerative cycle. Restoring NAD+ breaks this cycle: more substrate enables both sirtuin-mediated gene regulation and direct PARP-mediated repair simultaneously.

Epithalon and NAD+ embody two distinct scientific theories about what drives cellular aging:

Telomere theory (Epithalon's target): Aging is driven by progressive telomere shortening that limits replicative capacity. Stem cells and tissue-regenerating cells that cannot divide eventually exhaust their ability to replace damaged or dead cells, leading to organ decline.

Metabolic/epigenetic theory (NAD+'s target): Aging is driven by declining energy metabolism efficiency and the epigenetic dysregulation it causes. Declining NAD+ impairs sirtuins, which are epigenetic regulators. Loss of sirtuin activity allows epigenetic noise to accumulate — genes that should be silent become active, genes that should be active are silenced.

Both theories have empirical support. Both are probably partially correct. Comprehensive longevity research protocols address both.

Epithalon's evidence base is significant but concentrated. The majority of published research comes from Khavinson's group, primarily in Russian and Eastern European journals. Animal lifespan studies show consistent effects: fruit fly lifespan extension of 11-16%, transgenic mouse lifespan extension of 13%, and improved aging biomarkers in multiple rodent and primate studies. The published telomerase activation in human fetal somatic cells is notable — but has not been widely replicated by independent Western research groups.

NAD+'s evidence base is broader and more internationally replicated. Multiple independent labs have confirmed NAD+ decline with aging, NAD+-boosting effects in aging rodents, and human clinical trial data showing NAD+ supplementation safely raises blood NAD+ levels in older adults with measurable target engagement. The mechanism (required coenzyme substrate) is confirmed biochemistry, not dependent on findings from a single research group.

Neither compound has Phase 3 longevity trial data in humans — this is the frontier regardless of compound.

Because Epithalon and NAD+ target distinct aging mechanisms — telomere maintenance versus metabolic/sirtuin function — they are not redundant in a multi-compound protocol. Aging cells simultaneously experience telomere shortening and NAD+ decline, meaning both vulnerabilities exist in the same tissue at the same time.

Advanced longevity research protocols often combine compounds targeting multiple aging mechanisms: Epithalon for telomere maintenance, NAD+ for sirtuin substrate and DNA repair, MOTS-c for metabolic signaling, SS-31 for mitochondrial membrane protection, and GHK-Cu for tissue remodeling. Each addresses a different validated aging pathway.

Optimal combination sequencing — cycles vs. continuous vs. alternating — reflects genuine uncertainty in the field. No published protocols have established definitive timing for multi-compound longevity research in humans.

For Epithalon: The telomerase activation evidence is biologically plausible and the Khavinson literature is substantial, but represents a narrow research tradition with limited independent replication in Western peer-reviewed journals. Researchers entering this area should treat it with appropriate scientific rigor for findings from a concentrated research group. The compound is generally well tolerated in published studies with no significant adverse events at standard doses.

For NAD+: The mechanism is well-established biochemistry, the evidence base is internationally replicated, and human pharmacokinetic data confirms target engagement. Researchers have stronger mechanistic confidence and more independent confirmation. Practical limitation: IV NAD+ achieves the highest tissue concentrations but requires more logistical infrastructure; oral precursors (NMN, NR) are more practical but show variable tissue concentrations depending on cell type and conversion efficiency.

Both are legitimate research tools addressing different questions — and different aspects of what makes cells age.